AR121566A1 - Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismas - Google Patents

Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismas

Info

Publication number
AR121566A1
AR121566A1 ARP210100641A ARP210100641A AR121566A1 AR 121566 A1 AR121566 A1 AR 121566A1 AR P210100641 A ARP210100641 A AR P210100641A AR P210100641 A ARP210100641 A AR P210100641A AR 121566 A1 AR121566 A1 AR 121566A1
Authority
AR
Argentina
Prior art keywords
nirogacestat
therapy
bcma
combination therapy
subject
Prior art date
Application number
ARP210100641A
Other languages
English (en)
Inventor
Todd Webster Shearer
Badreddin Edris
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of AR121566A1 publication Critical patent/AR121566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento del cáncer o la amiloidosis de cadenas ligeras en un sujeto que lo necesita que comprende administrar una terapia de combinación que comprende una cantidad efectiva de la forma A de dihidrobromuro de nirogacestat y una terapia dirigida por el antígeno de maduración de células B (BCMA) al sujeto y usos de los mismos.
ARP210100641A 2020-03-13 2021-03-12 Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismas AR121566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13

Publications (1)

Publication Number Publication Date
AR121566A1 true AR121566A1 (es) 2022-06-15

Family

ID=75396879

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100641A AR121566A1 (es) 2020-03-13 2021-03-12 Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismas

Country Status (16)

Country Link
US (1) US20230121547A1 (es)
EP (1) EP4132515A1 (es)
JP (1) JP2023517243A (es)
KR (1) KR20230009873A (es)
CN (1) CN115916188A (es)
AR (1) AR121566A1 (es)
AU (1) AU2021236340A1 (es)
BR (1) BR112022018251A2 (es)
CA (1) CA3171267A1 (es)
CL (1) CL2022002479A1 (es)
CO (1) CO2022014388A2 (es)
IL (1) IL296075A (es)
MX (1) MX2022011258A (es)
PE (1) PE20230614A1 (es)
TW (1) TW202200132A (es)
WO (1) WO2021183934A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4396159A1 (en) 2021-09-01 2024-07-10 Springworks Therapeutics, Inc. Synthesis of nirogacestat
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN118338900A (zh) * 2021-11-05 2024-07-12 斯普林渥克斯治疗有限公司 含尼罗加司他的组合物和治疗
AU2022396239A1 (en) * 2021-11-23 2024-06-06 Teva Pharmaceuticals International Gmbh Solid state forms of nirogacestat salts
US11872211B2 (en) 2022-05-20 2024-01-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
WO2024183739A1 (zh) * 2023-03-09 2024-09-12 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120065A1 (en) * 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
BR112018001480A2 (pt) * 2015-07-24 2018-09-11 Oncotracker Inc moduladores de gama secretase para o tratamento de disfunção do sistema imunológico
US11845803B2 (en) * 2017-02-17 2023-12-19 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
EP3615055A1 (en) * 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JP7233425B2 (ja) * 2017-11-06 2023-03-06 ジュノー セラピューティクス インコーポレイテッド 細胞療法とガンマセクレターゼ阻害剤との組み合わせ
US11970542B2 (en) * 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies
US20210069194A1 (en) * 2018-01-17 2021-03-11 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
JP2021526517A (ja) * 2018-05-24 2021-10-07 アヤラ ファーマシューティカルズ インコーポレイテッド ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物および免疫療法剤を含む組成物ならびにそれらの使用方法
US11492409B2 (en) * 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
KR20210150488A (ko) * 2019-04-10 2021-12-10 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 항 bcma 항체 및 감마 세크레타제 억제제의 조합 요법
CA3150424A1 (en) * 2019-08-09 2021-02-18 Pfizer Inc. Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
JP2023517243A (ja) 2023-04-24
MX2022011258A (es) 2023-01-11
TW202200132A (zh) 2022-01-01
KR20230009873A (ko) 2023-01-17
CL2022002479A1 (es) 2023-08-18
CO2022014388A2 (es) 2023-02-16
IL296075A (en) 2022-11-01
US20230121547A1 (en) 2023-04-20
WO2021183934A1 (en) 2021-09-16
EP4132515A1 (en) 2023-02-15
AU2021236340A1 (en) 2022-09-29
BR112022018251A2 (pt) 2022-11-08
CA3171267A1 (en) 2021-09-16
PE20230614A1 (es) 2023-04-14
CN115916188A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
AR121566A1 (es) Una terapia de combinación con nirogacestat y una terapia dirigida por bcma y usos de las mismas
CO2019005287A2 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CL2022002808A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
PE20120998A1 (es) Metodos para el tratamiento del cancer usando antagonistas de notch
UY32359A (es) Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento
CO2024003949A2 (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
GT201600250A (es) Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer
AR100666A1 (es) Criopreservación de células cancerosas apoptóticas para utilizar en la inmunoterapia contra el cáncer, composición farmacéutica, kit
PE20211266A1 (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
CO2023001561A2 (es) Combinaciones para el tratamiento de cáncer
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
ECSP23076906A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CO2022007361A2 (es) Terapia de combinación para el tratamiento de cáncer cerebral
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a